NTRK3 fusion
NTRK3 fusion
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
gemcitabine + docetaxel
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
LV5FU2
Sensitive: A2 - Guideline
|
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
nivolumab
Sensitive: A2 - Guideline
|
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
|
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
nivolumab + ipilimumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
FOLFOX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
CAPOX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
bevacizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
FOLFIRI
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
albumin-bound paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
GTX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
FOLFOXIRI
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
mFOLFOX6
Sensitive: A2 - Guideline
|
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
selpercatinib
Sensitive: C1 - Off-label
|
PTEN mutation + MSI-H/dMMR
PTEN mutation + MSI-H/dMMR
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
PD1 inhibitor
Resistant: C3 – Early Trials
|
dMMR/MSI-H + TMB-L
dMMR/MSI-H + TMB-L
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
PD1 inhibitor
Resistant: C3 – Early Trials
|
MSI-H/dMMR + TMB-H + PD-L1 overexpression
MSI-H/dMMR + TMB-H + PD-L1 overexpression
|
Small Intestinal Carcinoma
Small Intestinal Carcinoma
|
nivolumab + ipilimumab
Sensitive: C4 – Case Studies
|
